Sendeyo K - Search Results

1

A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system.

Burlion A, Ramos RN, Kc P, Sendeyo K, Corneau A, Ménétrier-Caux C, Piaggio E, Olive D, Caux C, Marodon G. Burlion A, et al. Among authors: sendeyo k. Oncoimmunology. 2019 Apr 12;8(7):1596005. doi: 10.1080/2162402X.2019.1596005. eCollection 2019. Oncoimmunology. 2019. PMID: 31143518 Free PMC article.

2

Inhibition of the JAK/STAT Signaling Pathway in Regulatory T Cells Reveals a Very Dynamic Regulation of Foxp3 Expression.

Goldstein JD, Burlion A, Zaragoza B, Sendeyo K, Polansky JK, Huehn J, Piaggio E, Salomon BL, Marodon G. Goldstein JD, et al. Among authors: sendeyo k. PLoS One. 2016 Apr 14;11(4):e0153682. doi: 10.1371/journal.pone.0153682. eCollection 2016. PLoS One. 2016. PMID: 27077371 Free PMC article.

3

Expression of CMIP in podocytes is restricted to specific classes of lupus nephritis.

Bouachi K, Moktefi A, Zhang SY, Oniszczuk J, Sendeyo K, Remy P, Audard V, Pawlak A, Ollero M, Sahali D. Bouachi K, et al. Among authors: sendeyo k. PLoS One. 2018 Nov 15;13(11):e0207066. doi: 10.1371/journal.pone.0207066. eCollection 2018. PLoS One. 2018. PMID: 30439969 Free PMC article.

4

Upregulation of c-mip is closely related to podocyte dysfunction in membranous nephropathy.

Sendeyo K, Audard V, Zhang SY, Fan Q, Bouachi K, Ollero M, Rucker-Martin C, Gouadon E, Desvaux D, Bridoux F, Guellaën G, Ronco P, Lang P, Pawlak A, Sahali D. Sendeyo K, et al. Kidney Int. 2013 Mar;83(3):414-25. doi: 10.1038/ki.2012.426. Epub 2013 Jan 9. Kidney Int. 2013. PMID: 23302718 Free PMC article.

5

CMIP is a negative regulator of T cell signaling.

Oniszczuk J, Sendeyo K, Chhuon C, Savas B, Cogné E, Vachin P, Henique C, Guerrera IC, Astarita G, Frontera V, Pawlak A, Audard V, Sahali D, Ollero M. Oniszczuk J, et al. Among authors: sendeyo k. Cell Mol Immunol. 2020 Oct;17(10):1026-1041. doi: 10.1038/s41423-019-0266-5. Epub 2019 Aug 8. Cell Mol Immunol. 2020. PMID: 31395948 Free PMC article.

6

Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.

Izzedine H, Mangier M, Ory V, Zhang SY, Sendeyo K, Bouachi K, Audard V, Péchoux C, Soria JC, Massard C, Bahleda R, Bourry E, Khayat D, Baumelou A, Lang P, Ollero M, Pawlak A, Sahali D. Izzedine H, et al. Among authors: sendeyo k. Kidney Int. 2014 Feb;85(2):457-70. doi: 10.1038/ki.2013.344. Epub 2013 Sep 25. Kidney Int. 2014. PMID: 24067439 Free article.

7

Immunopathogenesis of idiopathic nephrotic syndrome with relapse.

Sahali D, Sendeyo K, Mangier M, Audard V, Zhang SY, Lang P, Ollero M, Pawlak A. Sahali D, et al. Among authors: sendeyo k. Semin Immunopathol. 2014 Jul;36(4):421-9. doi: 10.1007/s00281-013-0415-3. Epub 2014 Jan 9. Semin Immunopathol. 2014. PMID: 24402710 Free PMC article. Review.

8

NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome.

Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, Pawlak A, Audard V, Ollero M, Guigonis V, Sahali D. Boumediene A, et al. Among authors: sendeyo k. J Autoimmun. 2018 Mar;88:91-102. doi: 10.1016/j.jaut.2017.10.006. Epub 2017 Oct 19. J Autoimmun. 2018. PMID: 29056249 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page